Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Medical Oncology
Mayo
Questions discussed in this category
What is your approach to mitigating the infection risk with bispecific antibodies in multiple myeloma?
4 Answers available
How do you choose between the different recently approved Bispecifics Antibodies for Relapsed/Refractory Multiple Myeloma?
I.e. dosing regimen frequency, side effect profile, duration of follow up, etc.
3 Answers available
How do you manage IgM related peripheral neuropathy?
Do you utilize rituximab or any other specific management strategies?
2 Answers available
Do you recommend routinely getting periodic 24-hour urine monoclonal protein study for patients with active multiple myeloma?
If so, why?
4 Answers available
16704
17254
17010
15729
Papers discussed in this category
Leukemia, 2022 Feb 21
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
Br J Haematol, 2023 Jun 07
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Related Topics in Medical Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers